Short answer
Neurocrine Biosciences Inc (NBIX) filed its Q2 2018 10-Q quarterly report on Jul 31, 2018 for the quarter ended Jun 30, 2018.
Neurocrine Biosciences Inc Q2 2018 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Q2 revenue $96.9M, up from $6.3M YoY, entirely from INGREZZA product sales
- Q2 net loss $5.9M vs $60.0M YoY, while R&D expense increased to $37.0M from $21.9M
- INGREZZA strongest product line, $96.9M Q2 sales; cost of product sales $0.9M vs $0.1M
- Operating cash use $18.0M in six months vs $125.6M YoY; cash and investments $763.6M vs $767.8M
- Existing resources expected to fund at least 12 months, with potential additional funding needs for commercialization and R&D
Risk Factors
- No material changes overall, with starred risk factors updated from the December 31, 2017 10-K
- Regulatory risk: ACA changes, including 70% Medicare Part D coverage-gap discounts beginning January 1, 2019
- Operational risk: single-source suppliers for INGREZZA and active ingredients, creating shortage exposure
- Competitive risk: Teva’s AUSTEDO approval in August 2017 intensifying tardive dyskinesia competition
- Financial risk: $517.5 million of 2.25% convertible senior notes due 2024 limiting liquidity flexibility
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Neurocrine Biosciences Inc quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.